Panlin Capital

Panlin Capital is a Shanghai-based venture capital firm specializing in early-stage investments across sectors such as technology, healthcare, consumer goods, life sciences, and retail within China. The firm is dedicated to identifying and nurturing entrepreneurs among scientists and fostering innovators among entrepreneurs.

Established in 2010, Panlin Capital has managed assets exceeding RMB 5 billion and has invested in nearly 100 portfolio companies. The firm's investment strategy emphasizes technological innovation and consumption upgrades, targeting startups in biotechnology and data intelligence sectors.

In July 2023, Panlin Capital closed its 12th RMB-denominated fund, the Chengdu Panlin Xiangxu Fund, marking its first fund established in Chengdu. This fund focuses on To B and technology fields, investing in companies that enhance cost reduction, efficiency improvement, and quality enhancement for business clients, as well as hard technology enterprises with autonomous control over domestic replacement or key technologies. The fund has completed investments in several tech projects, including Percipio.XYZ, Chipanalog, Terapark, AIPlanck, Easylogic, Ruiyun Cold Chain, Ele007.com, and O-cubes.

Panlin Capital's portfolio includes notable companies such as Shenzhen Kangtai Biological Products Co., Ltd., a company listed on the Shenzhen Stock Exchange. The firm's investment philosophy centers on supporting China's independent innovation technology companies, aiming to drive growth and development in the country's technological landscape.